Market Research Logo

Global Immunology Market to 2022 - Large pipeline and competitive market to drive long-term market growth

Global Immunology Market to 2022 - Large pipeline and competitive market to drive long-term market growth

Summary

Immune-mediated inflammatory diseases are a very common set of chronic disorders that affect 5–7% of western populations. Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a highly genericized class of systemic small-molecule-based agents, are used in the first-line treatment of these diseases. These are supplemented in many cases by shorter-term glucocorticoid therapy, another class of highly genericized systemic agents.

However, as these therapies often fail to elicit an adequate long-term response, a large second-line therapy segment has emerged in these markets, beginning with the approval of Remicade (infliximab) and Enbrel (etanercept) in 1998. This segment consists largely of premium systemic monoclonal Antibodies (mAbs), which are highly commercially successful due to their widespread usage and high cost. Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth.

Scope

Although the patents for many of these mAbs either have already expired or are due to expire during the forecast period, the market is expected to experience continued growth, from $61.5 billion in 2015 to $74.2 billion in 2022, at a compound annual growth rate of 2.71%.

  • What factors are driving the market growth?
  • How can the factors limiting growth be overcome?
There is a very large pharmaceutical pipeline for immunology, consisting of 1,838 products in active development. However, the commercial performance of the products in the late-stage pipeline is expected to be moderate.
  • What gaps in the market are being addressed by the most promising of these late-stage pipeline products?
  • How does the composition of the pipeline compare with that of the existing market?
Several key commercially successful products, including Humira (adalimumab) and Remicade, are due to lose patent protection in the forecast period.
  • How will this affect their revenues in this period?
  • How are their manufacturers, AbbVie and Johnson & Johnson, responding to this?
The key players in the market, all of which are among the top 20 pharmaceutical companies, are expected to maintain their market lead throughout the forecast period.
  • What is driving this continued market dominance?
  • Who will the new market players be?
Reasons to buy

This report will allow you to -
  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis
  • Visualize the composition of the immunology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
  • Analyze the immunology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
  • Understand the growth in patient epidemiology and market revenues for the immunology market globally and across the key players and product types
  • Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological disorders
  • Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals


Global Immunology Treatment Market Will Exceed $74 Billion by 2022, says GBI Research

Despite the imminent patent expiry of many therapies, the global immunology treatment market is set to expand, from $61.5 billion in 2015 to reach $74.2 billion in 2022, says business intelligence provider GBI Research.

According to the company’s latest report*, the immunology treatment market’s Compound Annual Growth Rate (CAGR) will equal a relatively stable 2.71%, due to practical and regulatory barriers to entry for biosimilars that are not present for small molecule generics, and a moderately strong late-stage pipeline.

Dominic Trewartha, Managing Analyst for GBI Research, says: “This market is a lucrative area as up to 7% of western populations are thought to be affected by chronic immunological disorders. Consequently, the pharmaceutical pipeline for immunology is considerable, with 1,896 products currently in active development.

“While 85 of these are in Phase III of the process, it must be acknowledged that 73% of these pipeline products are in early developmental stages.”

GBI Research’s study suggests there are a number of prospective products expected to achieve strong annual revenues during the forecast period, although these are not anticipated to achieve revenues comparable to those generated by the current strongest-selling immunology products.

Trewartha explains: “To date, the most clinically and commercially effective drugs have been in a class of compounds known as monoclonal Antibodies (mAbs), which includes blockbuster products such as Humira (adalimumab) and Remicade (infliximab).

“APB-501, a biosimilar of Humira, which was the best-selling drug of 2014 worldwide, is anticipated to generate annual revenues of almost $1 billion by 2022, making it an exceptionally strong-performing non-patented drug.”

The analyst adds that while the immunology therapeutics market is a very commercially active area, with a number of exceptionally high-selling products present, revenues for these key drugs are expected to undergo a steady decline towards the end of the period.

Trewartha concludes: “GBI Research believes that revenues for immunology therapeutics will only significantly decline in the long term, beyond the forecast period. This is due to the protective effect of the practical and regulatory challenges in fielding biosimilar products, which reduces the impact of patent expiries on biologics, compared with small molecules.”

*Global Immunology Market to 2022 - Large pipeline and competitive market to drive long-term market growth

This report provides analysis of the immune-mediated inflammatory diseases treatment pipeline, stratified by stage of development, molecule type and molecular target. It includes information on the current clinical and commercial landscape, and the composition of the immunology therapeutics space in terms of dominant molecule types and targets, as well as highlighting key market players and their future prospects.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Therapy Area Introduction
2.2 Symptoms
2.3 Etiology and Pathophysiology
2.4 Co-morbidities and Complications
2.5 Epidemiology Patterns and Forecasts – Prevalence, Patient Segmentation, Diagnostic and Treatment Usage Rates
2.5.1 Rheumatoid Arthritis
2.5.2 Psoriasis
2.5.3 Systemic Lupus Erythematosus
2.6 Treatment
2.6.1 Non-Biologic Disease-Modifying Anti-Rheumatic Drugs
2.6.2 Glucocorticoids
2.6.3 Biologics
3 Key Marketed Products
3.1 Overview
3.2 Humira (adalimumab)
3.3 Remicade (infliximab)
3.4 Enbrel (etanercept)
3.5 Rituxan (rituximab)
3.6 Stelara (ustekinumab)
3.7 Prograf (tacrolimus)
3.8 Cimzia (certolizumab pegol)
3.9 Simponi (golimumab)
3.10 Conclusion
4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.5 Conclusion
5 Multi-Scenario Market Forecast to 2022
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 Tumor Necrosis Factor-Alpha
5.3.2 Interleukin-6 and Interleukin-6 Receptor
5.3.3 Interleukins-1, 2, 5, 12, 17 and 23 and Receptors
5.3.4 Janus Kinases
5.3.5 Revenue and Market Share Analysis by Company
5.3.6 Assessment of Key Pipeline Products
6 Company Analysis and Positioning
6.1 Company Landscape
6.2 Marketed and Pipeline Portfolio Analysis
7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Year and Value
7.1.2 Deals by Stage of Development and Value
7.1.3 Deals by Molecule Type, Mechanism of Action and Value
7.1.4 Table for Licensing Deals Valued Above $100m
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Stage of Development and Value
7.2.3 Deals by Molecule Type, Mechanism of Action and Value
7.2.4 Table for Co-development Deals Valued Above $100m
8 Appendix
8.1 References
8.2 Table of All Clinical Stage Pipeline Products
8.3 Abbreviations
8.4 Disease List
8.5 Methodology
8.5.1 Coverage
8.5.2 Secondary Research
8.5.3 Market Size and Revenue Forecasts
8.5.4 Pipeline Analysis
8.5.5 Competitive Landscape
8.6 Contact Us
8.7 Disclaimer
1.1 List of Tables
Table 1: Immunology, Global, Epidemiology of Inflammatory Immunological Disorders, 2015
Table 2: Immunology Therapeutics Market, Global, Approved Indications for Humira, 2015
Table 3: Immunology Therapeutics Market, Global, Approved Indications for Remicade, 2015
Table 4: Immunology Therapeutics Market, Global, Approved Indications for Enbrel, 2015
Table 5: Immunology Therapeutics Market, Global, Approved Indications for Rituxan, 2015
Table 6: Immunology Therapeutics Market, Global, Approved Indications for Stelara, 2015
Table 7: Immunology Therapeutics Market, Global, Approved Indications for Prograf, 2015
Table 8: Immunology Therapeutics Market, Global, Approved Indications for Cimzia, 2015
Table 9: Immunology Therapeutics Market, Global, Approved Indications for Simponi, 2015
Table 10: Immunology, Global, Annual Revenue Forecast for Key Products ($m), 2014–2022
Table 11: Immunology, Global, Usage of Generics Across Key Indications, 2015
Table 12: Immunology Therapeutics Market, Global, Forecast Revenues by Company, 2014–2022
Table 13: Immunology Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006–2015
Table 14: Immunology Therapeutics Market, Global, Co-Development Deals Valued Above $100m, 2006–2015
Table 15: Immunology, Global, Table of all Clinical Stage Pipeline Products, 2015
1.2 List of Figures
Figure 1: Immunology, Global, Epidemiology Patterns for Rheumatoid Arthritis (million), 2015–2022
Figure 2: Immunology, Global, Epidemiology Patterns for Psoriasis, Patients (million), 2015–2022
Figure 3: Immunology, Global, Epidemiology for Systemic Lupus Erythematosus (‘000), 2015–2022
Figure 4: Immunology, Global, Key Marketed Products and Approved Indications, 2015
Figure 5: Immunology Therapeutics Market, Global, Annual Revenues for Humira ($bn), 2006–2022
Figure 6: Immunology Therapeutics Market, Global, Annual Revenues for Remicade ($bn), 2006–2022
Figure 7: Immunology Therapeutics Market, Global, Annual Revenues for Enbrel ($bn), 2006–2022
Figure 8: Immunology Therapeutics Market, Global, Annual Revenues for Rituxan ($bn), 2006–2022
Figure 9: Immunology Therapeutics Market, Global, Annual Revenues for Stelara ($bn), 2010–2022
Figure 10: Immunology Therapeutics Market, Global, Annual Revenues for Prograf ($bn), 2006–2022
Figure 11: Immunology Therapeutics Market, Global, Annual Revenues for Cimzia ($bn), 2006–2022
Figure 12: Immunology Therapeutics Market, Global, Annual Revenues for Simponi ($bn), 2006–2022
Figure 13: Immunology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2015
Figure 14: Immunology Therapeutics Market, Global, Pipeline for Immunology by Stage of Development, Molecule Type and Program Type, 2015
Figure 15: Immunology Therapeutics Market, Global, Pipeline for Key Immunology Indications by Stage of Development, 2015
Figure 16: Immunology Therapeutics Market, Global, Pipeline for Key Immunology Indications by Molecule Type, 2015
Figure 17: Immunology Therapeutics Market, Global, Pipeline for Immunology by Molecular Target, 2015
Figure 18: Immunology Therapeutics Market, Global, Pipeline for Key Immunology Indications by Molecular Target, 2015
Figure 19: Immunology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006–2015
Figure 20: Immunology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006–2015
Figure 21: Immunology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006–2015
Figure 22: Immunology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006–2015
Figure 23: Immunology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2015
Figure 24: Immunology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2015
Figure 25: Immunology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2015
Figure 26: Immunology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2015
Figure 27: Immunology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (patients), 2006–2015
Figure 28: Immunology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2015
Figure 29: Immunology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2015
Figure 30: Immunology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006–2015
Figure 31: Immunology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006–2015
Figure 32: Immunology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006–2015
Figure 33: Immunology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2015
Figure 34: Immunology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006–2015
Figure 35: Immunology, Global, Market Size ($m), 2015–2022
Figure 36: Immunology, Global, Annual Revenue Forecast for Key Products ($m), 2014–2022
Figure 37: Immunology, Global, Annual Revenue Forecast for Tumor Necrosis Factor-Alpha Inhibitors ($bn), 2014–2022
Figure 38: Immunology, Global, Annual Revenue Forecast for Interleukin-6 Inhibitors ($bn), 2014–2022
Figure 39: Immunology, Global, Annual Revenue Forecast for Interleukin Inhibitors ($bn), 2015–2022
Figure 40: Immunology, Global, Annual Revenue Forecast for Janus Kinase Inhibitors ($bn), 2014–2022
Figure 41: Immunology Therapeutics Market, Global, Forecast Market Share by Company (%), 2014–2022
Figure 42: Immunology, Global, Companies by Compound Annual Growth Rate (%), 2014–2022
Figure 43: Immunology, Global, Revenues by Product Type, 2014–2022
Figure 44: Immunology, Global, AbbVie Annual Revenue Forecast ($bn), 2014–2022
Figure 45: Immunology, Global, Johnson & Johnson Annual Revenue Forecast ($m), 2014–2022
Figure 46: Immunology, Global, Roche Annual Revenue Forecast ($m), 2014–2022
Figure 47: Immunology, Global, Amgen Annual Revenue Forecast ($m), 2014–2022
Figure 48: Immunology, Global, Novartis Annual Revenue Forecast ($m), 2014–2022
Figure 49: Immunology Therapeutics Market, Global, Revenue Forecast for baricitinib ($m), 2015–2022
Figure 50: Immunology Therapeutics Market, Global, Revenue Forecast for ABP-501 ($m), 2015–2022
Figure 51: Immunology Therapeutics Market, Global, Revenue Forecast for ixekizumab ($m), 2015–2022
Figure 52: Immunology Therapeutics Market, Global, Revenue Forecast for sarilumab ($m), 2015–2022
Figure 53: Immunology Therapeutics Market, Global, Revenue Forecast for AMG-827 ($m), 2015–2022
Figure 54: Immunology, Global, Companies by Type, 2015
Figure 55: Immunology, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Immunology Specialization, 2015
Figure 56: Immunology, Global, Proportion of Total Company Revenue Attributed to Immunology, 2014–2022
Figure 57: Immunology, Global, Licensing Deals, 2006–2015
Figure 58: Immunology, Global, Licensing Deals by Indication and Value, 2006–2015
Figure 59: Immunology, Global, Licensing Deals, 2006–2015
Figure 60: Immunology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006–2015
Figure 61: Immunology, Global, Co-development Deals, 2006–2015
Figure 62: Immunology, Global, Co-development Deals by Indication and Value, 2006–2015
Figure 63: Immunology, Global, Co-development Deals, 2006–2015
Figure 64: Immunology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006–2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report